• Zenas BioPharma will host a virtual obexelimab IgG4-RD investor event on Sept. 29, 2026, from 8:00-9:30 a.m. ET.
• Session will cover IgG4-RD treatment landscape, unmet need, prelaunch planning, commercial opportunity for obexelimab if cleared by the FDA.
• FDA accepted the obexelimab IgG4-RD BLA in August 2026; PDUFA target action date set for May 27, 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080705PRIMZONEFULLFEED9822495) on September 08, 2026, and is solely responsible for the information contained therein.